Abstract

Recombinant human brain natriuretic peptide titanium is an endogenous peptide hormone synthesized using modern gene recombination technology. It has the same amino acid sequence, spatial structure, and biological activity as endogenous brain natriuretic peptide synthesized in ventricular muscle. Clinically, it is mainly used to treat acute decompensated heart failure. We aim to analyze its impact on the short-term prognosis of elderly patients with acute myocardial infarction after percutaneous coronary intervention. Elderly patients with acute myocardial infarction who underwent percutaneous coronary intervention treatment were divided into a recombinant human brain sodium titanium group and a control group based on whether to use recombinant human brain sodium titanium. The analysis indicators include cardiovascular risk factors, cardiac function indicators, incidence of major adverse cardiac events, and adverse drug reactions at admission and 2 w after treatment. A total of 72 patients were included, with an average age of (67.4±6.7) y, of which 69.04 % were male. After 2 w of treatment, the B-type natriuretic peptide levels in both groups of patients were lower than before treatment, with a significant decrease in the recombinant human brain natriuretic titanium group. However, the left ventricular ejection fraction of the recombinant human brain natriuretic titanium group was lower than before treatment in the same group, while the left ventricular ejection fraction level of the control group was higher than before treatment in the same group, and the differences were not statistically significant. Two patients in the recombinant human brain sodium urinary titanium group experienced hypotension, with an adverse reaction rate of 5 % (2/40); one patient in the control group stopped using dopamine due to palpitations and sinus tachycardia, one patient stopped using nitroglycerin due to headache, and one patient stopped using nitroglycerin due to hypotension. The adverse reaction rate was 9.38 % (3/32). Recombinant human brain natriuretic titanium is safe and effective for patients with acute myocardial infarction, while also improving cardiovascular disease risk factors.